Nintedanib Ethanesulfonate Salt

Catalog No.S5234 Batch:S523403

Print

Technical Data

Formula

C31H33N5O4.C2H6O3S

Molecular Weight 649.76 CAS No. 656247-18-6
Solubility (25°C)* In vitro DMSO 100 mg/mL (153.9 mM)
Water 100 mg/mL (153.9 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Nintedanib (Intedanib, BIBF 1120) is a small molecule tyrosine-kinase inhibitor with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β, respectively.
Targets
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
PDGFRα [1]
(Cell-free assay)
View More
13 nM 13 nM 34 nM 37 nM 59 nM

Protocol (from reference)

Selleck's Nintedanib Ethanesulfonate Salt has been cited by 16 publications

Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study [ Am J Cancer Res, 2023, 13(2):355-378] PubMed: 36895976
Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells [ Theranostics, 2022, 12(2):747-766] PubMed: 34976211
Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanoma [ EMBO Mol Med, 2022, 14(3):e15295] PubMed: 35156321
FOXA1 prevents nutrients deprivation induced autophagic cell death through inducing loss of imprinting of IGF2 in lung adenocarcinoma [ Cell Death Dis, 2022, 13(8):711] PubMed: 35974000
Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A165 No Longer Depends on the Growth Factor's Presence [ Biomolecules, 2022, 12(5)734] PubMed: 35625661
Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro [ Sci Rep, 2022, 12(1):12493] PubMed: 35864147
Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients [ Anticancer Drugs, 2022, 10.1097/CAD.0000000000001344] PubMed: 36066384
Contracting scars from fibrin drops [ Integr Biol (Camb), 2022, 14(1):1-12] PubMed: 35184163
Targeting fibroblast growth factor receptors to combat aggressive ependymoma [ Acta Neuropathol, 2021, 10.1007/s00401-021-02327-x] PubMed: 34046693
The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease [ Cell Death Dis, 2021, 12(10):947] PubMed: 34650051

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.